Pancreatic Neuroendocrine Neoplasm
NCI Definition: A neoplasm with neuroendocrine differentiation that arises from the pancreas. It includes neuroendocrine tumors (low and intermediate grade) and neuroendocrine carcinomas (high grade). 
Pancreatic neuroendocrine neoplasms most frequently harbor alterations in MEN1, DAXX, ATRX, TP53, and TSC2 .
DAXX Mutation, MEN1 Mutation, MEN1fs, ATRX Mutation, and TP53 Mutation are the most common alterations in pancreatic neuroendocrine neoplasm .
There are 2 clinical trials for pancreatic neuroendocrine neoplasm, of which 0 are open and 2 are completed or closed. Of the trials that contain pancreatic neuroendocrine neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (0 open).
Everolimus is the most common intervention in pancreatic neuroendocrine neoplasm clinical trials.
Significant Genes in Pancreatic Neuroendocrine Neoplasm
VHL is altered in 4.9% of pancreatic neuroendocrine neoplasm patients .
VHL is an inclusion eligibility criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains VHL status and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.